BioSpace News Archive

Pliant Therapeutics, Inc. today announced senior management’s participation at the following investor events in March.

BioNxt Solutions Inc. is pleased to report that it has executed an agreement to carry out its comparative drug absorption study for the Company’s transdermal Rotigotine patch for the treatment of Parkinson’s disease.

The European Commission has granted marketing authorisation in the European Union for darolutamide, an oral androgen receptor inhibitor, plus androgen deprivation therapy in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Chroma Medicine, Inc. announced the completion of a $135 million Series B financing led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management.

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported its financial and operational results for the first quarter ended December 31, 2022.

Biostage, Inc. announced that effective as of March 1, 2023, its existing director since November 2021, Mr. Jerry He, was appointed Chairman of the Board and hired as Chief Executive Officer.

Oncternal Therapeutics, Inc. announced that it has granted an inducement award to one new employee, Yelena Tsabur, who joined Oncternal as Associate Clinical Trial Manager.

Owens & Minor, Inc. (NYSE: OMI) announced today that executive leadership will participate in a fireside chat at the upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference.